Blood sugar marker may reveal hidden heart damage after attack
NCT ID NCT07261514
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 674 people who had a severe type of heart attack (STEMI) and were treated with a procedure to open blocked arteries. Researchers checked if a simple blood test called the triglyceride glucose (TyG) index could predict how much heart muscle was damaged and the risk of future problems like another heart attack or heart failure. They found that a higher TyG index was linked to more heart damage and worse outcomes, suggesting this test could help doctors identify high-risk patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
674 people
The number who actually took part.
- Started
-
Jan 2014
- Finished
-
May 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
primary PCI-treated patients with acute STEMI
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1\) patients meet diagnostic criteria for STEMI-"The priority for these patients is the implementation of reperfusion therapy as soon as possible .In the appropriate clinical context,ST-segment elevation (accessed at the J-point) indicates possible acute coronary artery in the following situations:New ST elevation at the J-point in at least two contiguous leads:·≥ 2.5 mm in men under 40years,≥2mm in males 40 years and older,or ≥1.5mmin women relatively less of age in leads V2-V3,and/or ≥1mm in the other leads (in the absence of left ventricular hypertrophy or left bundle branch block) Post-STEMI reperfusion with PCI, diagnosis and treatment strategy in accordance with current diagnosis and treatment standards and guidelines27" and complete pPCI within 48h-"" diagnostic strategy meets current diagnostic criteria and guidelines;2) KillIP\<3 and consent to CMR examination and follow-up observation, and CMR examination is completed within 7 days after surgery. 3) Monitor baseline blood glucose and baseline triglycerides during admission. Exclusion criteria: 1) Patients with NSTEMI 2) Lack of clinical data 3) Presence of contraindications to CMR examination-such as implantable cardiac pacemaker, clo gadolinium contrast agent or renal insufficiency; meanwhile, patients with Killip IV cardiac function or clinical instability, and patients with valvular disease, congenital heart disease, pulmonary hypertension, cardiomyopathy history, persistent atrial fibrillation, etc. affecting cardiac structure and function parameters were excluded; Patients with previous history of myocardial infarction, coronary artery intervention and coronary artery bypass grafting were also excluded; patients with severe clinical diseases such as severe hematological diseases, infectious diseases, malignant tumors, liver and kidney failure, and mental disorders or intellectual disabilities who could not cooperate with examination and follow-up; 4) patients with poor MRI quality or sequence deletion were not included in the study. Exclusion Criteria: * Contraindications of CMR examination, such as implantable cardiac pacemaker, claustrophobia, allergy to gadolinium contrast agent or renal insufficiency; meanwhile, patients with Killip IV cardiac function or unstable clinical condition, as well as patients with valve disease, congenital heart disease, pulmonary hypertension, cardiomyopathy history, persistent atrial fibrillation, etc. affecting cardiac structure and function parameters shall be excluded; Patients with a history of myocardial infarction, coronary artery intervention, or coronary artery bypass grafting were also excluded. Patients with severe hematological diseases, infectious diseases, malignant tumors, liver and kidney failure, mental disorders or intellectual disabilities who could not cooperate with examination and follow-up, or poor or missing MRI images were not included in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ST elevation (stemi) myocardial infarction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100039, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart attack delay may signal kidney risk after angioplasty
- The heart rhythm threat hiding in heart attack wards
- Antioxidant infusion may shield the heart from reperfusion injury
- Blood test scores may reveal heart attack risk
- Can frailty scores predict heart attack survival in the elderly?
- Heart ultrasound clue may spot High-Risk attack patients